The U.S. Food and Drug Administration (FDA) has put a boxed warning onto this medicine because it may affect mood and increase the likelihood of suicidal thoughts in people under 25 years old. This is attributed to the<unk>  component, as antidepressants have been associated with increased risk of suicidal thoughts, but not suicide, and only in people younger than 25. The safety and effectiveness in children under the age of 18 has not been studied.
Naltrexone/bupropion
Amitriptyline/chlordiazepoxide
Olanzapine/fluoxetine
Aripiprazole/sertraline
Buprenorphine/naltrexone
Low-dose naltrexone
Brief psychotherapy
MDMA-assisted psychotherapy